Company profile: Cevec
1.1 - Company Overview
Company description
- Provider of biopharmaceutical production expertise using a unique human cell-based expression system, developing therapeutic proteins and monoclonal antibodies with human glycosylation patterns. CAP-Go enables production of proteins beyond antibodies, including complex glycosylated proteins that are difficult to express in conventional cell lines.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cevec
Microbiome Insights
HQ: Canada
Website
- Description: Provider of end-to-end microbiome DNA sequencing services and state-of-the-art bioinformatic analysis. Offerings include 16S V4 amplicon sequencing for taxonomic profiling, shotgun metagenomic sequencing for species-level and functional insights, short-chain fatty acid analysis in stool, qPCR for absolute abundance, and comprehensive bioinformatics processing and reporting.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Microbiome Insights company profile →
Genovis
HQ: United States
Website
- Description: Provider of SmartEnzymes enabling identification, characterization, and quality control of antibody-based biotherapeutics, including monoclonal antibodies, ADCs, and biosimilars. Offerings include FabRICATOR for rapid antibody digestion, FabALACTICA for IgG1 Fab profiling, TransGLYCIT for site-specific IgG glycan remodeling, SialEXO for mucin glycan engineering, and GlySERIAS for fusion protein analysis, plus technical support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genovis company profile →
ARTMS
HQ: Canada
Website
- Description: Provider of cyclotron-based technology for decentralized, local production of diagnostic imaging isotopes and purified radiopharmaceuticals. Offers the QUANTM Irradiation System (QIS) and QUANTM platforms for gallium-68, technetium-99m, zirconium-89, and copper-64, featuring automatic 2-way pneumatic transfer, a compact solid target station, and complete solid target processing solutions for PET and other clinical applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ARTMS company profile →
Afyren
HQ: France
Website
- Description: Provider of biotechnological and green chemistry solutions that valorize non-food biomass into biosourced molecules and natural organic acids. Offers AFYREN NEOXY production facility, FLAVYREN flavor and fragrance acids with a low carbon footprint, and a circular eco approach using organic waste and aiming for zero industrial waste via by-product valorization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Afyren company profile →
Biosyntia
HQ: Denmark
Website
- Description: Provider of synthetic biology and metabolic engineering solutions, developing biocatalysts and tailored biocatalysis processes using patent-pending high-throughput screening. Offers BIO-B7 natural biotin (high-purity, traceable), Eraglow skincare actives based on fermented biotin, and Forskeffect botanical forskolin. Provides Biosynthetic Selections for ultra-high-throughput testing of engineered microorganisms and partnering on fermentation process development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biosyntia company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cevec
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cevec
2.2 - Growth funds investing in similar companies to Cevec
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cevec
4.2 - Public trading comparable groups for Cevec
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →